On Friday, GSK ADR reached an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an improvement to 83, a rise from 65 the day before.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
GSK ADR is building a consolidation with a 45.92 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
GSK ADR posted negative growth for both the top and bottom lines last quarter. GSK ADR is expected to release its next quarterly numbers on or around Apr. 30.
GSK ADR earns the No. 4 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
